Synairgen PLC (AIM:SNG, OTC:SYGGF) has appointed seasoned pharmaceutical physician and drug developer Dr. Marcin Mankowski as chief medical officer, effective immediately.
Synairgen, which is developing SNG001, an investigational formulation for inhalation containing the immunomodulatory broad-spectrum antiviral protein interferon beta, created the new full-time role as clinical development progresses.
Dr. Mankowski was previously an acting CMO and clinical trials consultant with Synairgen since 2018.
Prior to joining Synairgen, Marcin co-founded and acted as chief executive at tranScrip, a leading contract drug development business. He has more than 27 years of experience in the industry.
"I look forward to be working more closely with and supporting the team at Synairgen as it progresses towards more targeted clinical trials of SNG001 to maximise the benefits of treatment and address the high unmet medical need,” said Dr. Mankowski.
Commenting on his appointment, Synairgen chief executive Richard Marsden said: “I am delighted that Marcin will be joining us as CMO in a full-time capacity.
"Since 2018, he has been supporting and guiding us on our clinical trials and his appointment today underlines his belief in our drug.
"Marcin's in-depth knowledge of the company and SNG001 as well as his strong track record in leading the strategy, design and implementation of global clinical development programmes, will be invaluable to us as we prepare to enter further clinical trials of SNG001."